SCIENCE
Gene Network Sciences Announces Michael Gilman as Board Member
Gene Network Sciences, Inc. (GNS) today announced that it has named Michael Gilman, Ph.D., Founder and Chief Executive Officer of Stromedix, Inc. and former Executive Vice President of Research at Biogen Idec, to its Board of Directors.
Dr. Gilman has been Founder and Chief Executive Officer of Stromedix since June 2006. He was previously Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. From 1994 to 1999, Dr. Gilman held several positions at ARIAD Pharmaceuticals, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology. He also serves on the Board of Directors of EPIX Pharmaceuticals, Inc.
"Michael Gilman's broad pharma research leadership experience will play a critical role in GNS's effectively deploying our REFS platform to accelerate pharma drug research and development," said Colin Hill, CEO of GNS. "I am looking forward to leveraging his experiences to create maximum impact for our partners."
"I was drawn to GNS by the power of the supercomputer-driven REFS platform to enable both new forms of discovery and new approaches to personalized medicine. The industry is at a crossroads, with advances in DNA sequencing finally paving the way to a more systematic exploration of disease biology and drug response markers. Data is no longer the bottleneck -- the analysis is. That's why I see technology such as GNS's as the missing link," said Dr. Gilman.
Dr. Gilman has been Founder and Chief Executive Officer of Stromedix since June 2006. He was previously Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. From 1994 to 1999, Dr. Gilman held several positions at ARIAD Pharmaceuticals, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology. He also serves on the Board of Directors of EPIX Pharmaceuticals, Inc.
"Michael Gilman's broad pharma research leadership experience will play a critical role in GNS's effectively deploying our REFS platform to accelerate pharma drug research and development," said Colin Hill, CEO of GNS. "I am looking forward to leveraging his experiences to create maximum impact for our partners."
"I was drawn to GNS by the power of the supercomputer-driven REFS platform to enable both new forms of discovery and new approaches to personalized medicine. The industry is at a crossroads, with advances in DNA sequencing finally paving the way to a more systematic exploration of disease biology and drug response markers. Data is no longer the bottleneck -- the analysis is. That's why I see technology such as GNS's as the missing link," said Dr. Gilman.